CoChat
Sign Up
Cited by 25Multiple Myeloma Research and TreatmentsBone health and treatmentsProtein Degradation and Inhibitors

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma

Hoy, Sheridan M.·2017·Drugs
DOI 10.1007/s40265-017-0833-y
Open this paper in CoChat — free account

Abstract

Pomalidomide (Imnovid®; Pomalyst®), an analogue of thalidomide, is an immunomodulatory agent, with several mechanisms of action (both direct and indirect) thought to be involved in its anti-myeloma activity. Oral pomalidomide is available in several countries for use in combination with low-dose dexamethasone in adults with relapsed and refractory multiple myeloma. In multinational, phase II or III studies in patients with refractory, or relapsed and refractory multiple myeloma who had received ≥ 2 prior treatment regimens (including ≥ 2 cycles of both lenalidomide and bortezomib), pomalidomide plus low-dose dexamethasone was associated with prolonged progression-free survival (PFS) and overall survival and an improved overall response rate. Pomalidomide plus low-dose dexamethasone had a manageable tolerability profile, with neutropenia, infections, anaemia and thrombocytopenia being the most frequently reported grade 3 or 4 treatment-emergent adverse events. In conclusion, pomalidomide plus low-dose dexamethasone extends the treatment options available for the management of relapsed and refractory multiple myeloma in a patient population that has very limited treatment options.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40265-017-0833-y

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 2 references

Research works printed but not linked: 26

  1. Dimopoulos MA, Richardson PG, Moreau P, et al. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015;12(1):42–54. · DOI
  2. Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9(1):52. · DOI
  3. Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54(4):683–7. · DOI · Paper page
  4. Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs. 2017;77(5):505–20. · DOI
  5. Bjorklund CC, Lu L, Kang J, et al. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer Journal. 2015;5:e354. · DOI · Paper page
  6. Zhu YX, Braggio E, Shi C-X, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118(18):4771–9. · DOI · Paper page
  7. Matsue K, Iwasaki H, Chou T, et al. Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma. Cancer Sci. 2015;106(11):1561–7. · DOI
  8. Kasserra C, Assaf M, Hoffmann M, et al. Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects. J Clin Pharmacol. 2015;55(2):168–78. · DOI
  9. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–66. · DOI
  10. Dimopoulos MA, Palumbo A, Corradini P, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128(4):497–503. · DOI
  11. Dimopoulos MA, Weisel KC, Song KW, et al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015;100(10):1327–33. · DOI
  12. San Miguel JF, Weisel KC, Song KW, et al. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica. 2015;100(10):1334–9. · DOI
  13. Morgan G, Palumbo A, Dhanasiri S, et al. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. Br J Haematol. 2015;168(6):820–3. · DOI
  14. Moreau P, Weisel KC, Song KW, et al. Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). Leuk Lymphoma. 2016;57(12):2839–47. · DOI
  15. Weisel K, Dimopoulos M, Song KW, et al. Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial. Clin Lymphoma Myeloma Leuk. 2015;15(9):519–30. · DOI
  16. Palumbo A, Dimopoulos MA, Richardson P, et al. A pooled analysis of the impact of age on outcomes in patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide + low-dose dexamethasone [abstract no. E1295]. Haematologica. 2016;101(Suppl 1):535–6.
  17. Ichinohe T, Kuroda Y, Okamoto S, et al. A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial. Exp Hematol Oncol. 2015;5:11. · DOI
  18. Chng WJ, Kim K, Huang J, et al. Pomalidomide plus dexamethasone (Pd) in the treatment of Asian patients with relapsed/refractory myeloma (RRMM) who are previously treated with bortezomib and refractory to lenalidomide: interim analysis of a trial by the Asian Myeloma Network (AMN) [abstract]. Blood. 2016;128(22):2130. · DOI
  19. Siegel DS, Weisel KC, Dimopoulos MA, et al. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leuk Lymphoma. 2016;57(12):2833–8. · DOI
  20. Weisel KC, Dimopoulos MA, Moreau P, et al. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica. 2016;101(7):872–8. · DOI
  21. Sonneveld P, Weisel K, van de Donk N, et al. MM-013 phase 2 multicenter study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and renal impairment (RI) [abstract no. P343]. In: 22nd Congress of the European Hematology Association (EHA). 2017. · DOI
  22. Maciocia N, Melville A, Cheesman S, et al. Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. Br J Haematol. 2017;176(6):908–17. · DOI
  23. Dechow T, Aldaoud A, Hurtz HJ, et al. Overall response rate of patients with refractory multiple myeloma treated with pomalidomide and low dose dexamethasone after lenalidomide failure: interim results of the POSEIDON study [abstract no. E1304]. Haematologica. 2016;101(Suppl 1):540.
  24. Dimopoulos MA, Roussou M, Kanellias N, et al. Pomalidomide with low dose dexamethasone is effective irrespective of primary or secondary resistance to lenalidomide but the IMiD-free interval is important [abstract]. Blood. 2016;128(22):3310. · DOI
  25. Moreau P, Dimopoulos MA, Richardson PG, et al. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: a pooled analysis. Eur J Haematol. 2017. doi: 10.1111/ejh.12903 . · DOI
  26. Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv52-iv61. · DOI

Cited by

Sorted by citations

Metadata

Authors
Hoy, S. M.
Affiliations
Springer Nature (New Zealand) (NZ)
Corresponding author
Hoy, Sheridan M.
Venue
Drugs
Publisher
Springer Science and Business Media LLC
Published
2017-11
Volume
77
Issue
17
Pages
1897-1908
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
DOI
10.1007/s40265-017-0833-y
OpenAlex
W2767903236
Cited by
25
References
2
Citations by year
2026: 3 · 2025: 3 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 2
FWCI
0.30
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (unspecified)
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
pomalidomide, relapsed/refractory multiple myeloma, low-dose dexamethasone, immunomodulators, thalidomide analogues, progression-free survival, overall survival, treatment-emergent adverse events, neutropenia, lenalidomide, bortezomib
MeSH terms
Adult, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Dose-Response Relationship, Drug, Female, Humans, Male, Multiple Myeloma, Recurrence, Thalidomide, Treatment Failure, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review